Guidance for Industry: Special Protocol Assessment
Rockville, MD: Center for Biologics Evaluation and Research, 2002 May; 10 p. [Online]. Available: http://www.fda.gov/cder/guidance/3764fnl.htm [2003 February 11]
Showing items related by title, author, creator and subject.
Guidance for Industry: Supplemental Guidance on Testing for Replication-Competent Retrovirus in Retroviral Vector-Based Gene Therapy Products and During Follow-Up of Patients in Clinical Trials Using Retroviral Vectors Center for Biologics Evaluation and Research [CBER] (United States) (2001-02-10)
Guidance for Industry: Gene Therapy Clinical Trials -- Observing Participants for Delayed Adverse Events: Draft Guidance Center for Biologics Evaluation and Research [CBER] (United States) (2005-08)